Mosaic ImmunoEngineering Inc. (CPMV) stock
CPMVOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.33+0.00 (0.00%)
Close on Oct 19, 2026Market cap $2.41MP/E –Yield –
Mosaic ImmunoEngineering operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Mosaic ImmunoEngineering's operating cash flow for the twelve months ending Jun 30, 2026 was -$53.56K. For fiscal 2025 it was -$111.40K. The highest annual figure on record is -$111.40K in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$111.40K | – |
| FY2024 | Dec 31, 2024 | -$241.16K | – |
| FY2023 | Dec 31, 2023 | -$497.47K | – |
| FY2022 | Dec 31, 2022 | -$690.13K | – |
| FY2020 | May 31, 2020 | -$986.76K | – |
| FY2019 | May 31, 2019 | -$760.77K | – |
| FY2018 | May 31, 2018 | -$880.17K | – |
| FY2017 | May 31, 2017 | -$1.31M | – |
| FY2016 | May 31, 2016 | -$1.58M | – |
| FY2015 | May 31, 2015 | -$1.34M | – |
| FY2014 | May 31, 2014 | -$1.50M | – |
| FY2013 | May 31, 2013 | -$1.01M | – |
| FY2012 | May 31, 2012 | -$2.40M | – |
| FY2011 | May 31, 2011 | -$4.32M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$46 | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$3.55K | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$28.14K | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$21.82K | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$32.35K | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$29.09K | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$20.72K | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$13.00K | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$116.31K | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$91.14K | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$96.72K | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$110.07K | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$118.81K | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$171.87K | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$163.49K | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$164.86K | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$172.06K | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$189.72K | – |
| Q4 FY2020CQ2 2020 | May 31, 2020 | -$176.91K | – |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | -$214.12K | – |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | -$275.71K | – |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | -$320.02K | – |
| Q4 FY2019CQ2 2019 | May 31, 2019 | -$229.12K | – |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | -$106.99K | – |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | -$164.34K | – |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | -$260.33K | – |
| Q4 FY2018CQ2 2018 | May 31, 2018 | -$209.35K | – |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | -$186.43K | – |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | -$255.47K | – |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | -$228.92K | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | -$386.07K | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | -$230.99K | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | -$274.59K | – |
| Q1 FY2017CQ3 2016 | Aug 31, 2016 | -$419.19K | – |
| Q4 FY2016CQ2 2016 | May 31, 2016 | -$360.08K | – |
| Q3 FY2016CQ1 2016 | Feb 29, 2016 | -$358.97K | – |
| Q2 FY2016CQ4 2015 | Nov 30, 2015 | -$307.81K | – |
| Q1 FY2016CQ3 2015 | Aug 31, 2015 | -$551.42K | – |
| Q4 FY2015CQ2 2015 | May 31, 2015 | -$332.61K | – |
| Q3 FY2015CQ1 2015 | Feb 28, 2015 | -$212.55K | – |
See a number that looks wrong?